Cargando…

62例CD20阳性多发性骨髓瘤患者临床特征分析

OBJECTIVE: To explore the clinical and laboratory characteristics of mutiple myeloma patients with CD20 expression. METHODS: Review the data of mutiple myeloma patients and analyze the clinical and laboratory characteristics of CD20 positive patients, compared with CD20 negative patients. RESULTS: ①...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343032/
https://www.ncbi.nlm.nih.gov/pubmed/25641146
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.01.011
_version_ 1783555675530461184
collection PubMed
description OBJECTIVE: To explore the clinical and laboratory characteristics of mutiple myeloma patients with CD20 expression. METHODS: Review the data of mutiple myeloma patients and analyze the clinical and laboratory characteristics of CD20 positive patients, compared with CD20 negative patients. RESULTS: ①Totally 465 cases of newly-diagnosed MM were collected with CD20 expression status detected by multi-color flow cytometry. Sixty two patients(13.3%) were CD20 positive and the others were negative. ②No statistical differences were found between CD20 positive and negative groups about the sex ratio, age predominance, D-S staging, ISS staging, renal insufficiency rate, platelet count, LDH level and classifications by paraprotein (all P value >0.05). ③Compared with those of CD20 negative patients, the hemoglobulin value(74.5 g/Lvs 83.5 g/L, P=0.021), extramedullary involvement rate (3.5% vs 13.7%, P= 0.029), CD56-positive rate (36.7% vs68.8%, P=0.000), t(4;14) translocation rate (2.4% vs 24.0%, P= 0.001) in CD20 positive patients were lower statistically. ④Compared with those of CD20 negative patients, the percentage of plasma cells (0.400 vs 0.295,P=0.045) by marrow smear differential counting, the percentage of myeloma cells (20.0% vs 6.8%, P=0.000) by multi-color flow cytometry analysis, CD45-positive rate (12.1% vs 4.5%, P=0.018), CD79a-positive rate (9.8% vs1.5%, P=0.013) and t(11;14) translocation rate (60.5% vs 14.4%, P=0.000) in CD20 positive patients were higher statistically. ⑤There was no statistical differences about the overall response rate (ORR), complete response rate (CRR), TTP(time to progression), PFS (progression free survival) and overall survival (OS) between CD20 positive and negative groups. CONCLUSION: CD20 positive rate is 13.3% in multiple myeloma pateints according to our data. CD20 poaitive myeloma were prone to residing in bone marrow and affecting erythropoiesis. Atypical immunophenotypes were more common, and the incidence of t(11;14) were increased markedly while that of t(4;14) were rare for CD20 positive multiple myeloma.
format Online
Article
Text
id pubmed-7343032
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73430322020-07-16 62例CD20阳性多发性骨髓瘤患者临床特征分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the clinical and laboratory characteristics of mutiple myeloma patients with CD20 expression. METHODS: Review the data of mutiple myeloma patients and analyze the clinical and laboratory characteristics of CD20 positive patients, compared with CD20 negative patients. RESULTS: ①Totally 465 cases of newly-diagnosed MM were collected with CD20 expression status detected by multi-color flow cytometry. Sixty two patients(13.3%) were CD20 positive and the others were negative. ②No statistical differences were found between CD20 positive and negative groups about the sex ratio, age predominance, D-S staging, ISS staging, renal insufficiency rate, platelet count, LDH level and classifications by paraprotein (all P value >0.05). ③Compared with those of CD20 negative patients, the hemoglobulin value(74.5 g/Lvs 83.5 g/L, P=0.021), extramedullary involvement rate (3.5% vs 13.7%, P= 0.029), CD56-positive rate (36.7% vs68.8%, P=0.000), t(4;14) translocation rate (2.4% vs 24.0%, P= 0.001) in CD20 positive patients were lower statistically. ④Compared with those of CD20 negative patients, the percentage of plasma cells (0.400 vs 0.295,P=0.045) by marrow smear differential counting, the percentage of myeloma cells (20.0% vs 6.8%, P=0.000) by multi-color flow cytometry analysis, CD45-positive rate (12.1% vs 4.5%, P=0.018), CD79a-positive rate (9.8% vs1.5%, P=0.013) and t(11;14) translocation rate (60.5% vs 14.4%, P=0.000) in CD20 positive patients were higher statistically. ⑤There was no statistical differences about the overall response rate (ORR), complete response rate (CRR), TTP(time to progression), PFS (progression free survival) and overall survival (OS) between CD20 positive and negative groups. CONCLUSION: CD20 positive rate is 13.3% in multiple myeloma pateints according to our data. CD20 poaitive myeloma were prone to residing in bone marrow and affecting erythropoiesis. Atypical immunophenotypes were more common, and the incidence of t(11;14) were increased markedly while that of t(4;14) were rare for CD20 positive multiple myeloma. Editorial office of Chinese Journal of Hematology 2015-01 /pmc/articles/PMC7343032/ /pubmed/25641146 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.01.011 Text en 2015年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
62例CD20阳性多发性骨髓瘤患者临床特征分析
title 62例CD20阳性多发性骨髓瘤患者临床特征分析
title_full 62例CD20阳性多发性骨髓瘤患者临床特征分析
title_fullStr 62例CD20阳性多发性骨髓瘤患者临床特征分析
title_full_unstemmed 62例CD20阳性多发性骨髓瘤患者临床特征分析
title_short 62例CD20阳性多发性骨髓瘤患者临床特征分析
title_sort 62例cd20阳性多发性骨髓瘤患者临床特征分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343032/
https://www.ncbi.nlm.nih.gov/pubmed/25641146
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.01.011
work_keys_str_mv AT 62lìcd20yángxìngduōfāxìnggǔsuǐliúhuànzhělínchuángtèzhēngfēnxī
AT 62lìcd20yángxìngduōfāxìnggǔsuǐliúhuànzhělínchuángtèzhēngfēnxī
AT 62lìcd20yángxìngduōfāxìnggǔsuǐliúhuànzhělínchuángtèzhēngfēnxī
AT 62lìcd20yángxìngduōfāxìnggǔsuǐliúhuànzhělínchuángtèzhēngfēnxī
AT 62lìcd20yángxìngduōfāxìnggǔsuǐliúhuànzhělínchuángtèzhēngfēnxī
AT 62lìcd20yángxìngduōfāxìnggǔsuǐliúhuànzhělínchuángtèzhēngfēnxī
AT 62lìcd20yángxìngduōfāxìnggǔsuǐliúhuànzhělínchuángtèzhēngfēnxī